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CLINICAL PATHOLOGIC CHALLENGE ANSWER
Tender Nodules on the Extremities: Answer
Allison Zarbo, MD, Kedar Inamdar, MD, PhD, and Ben J. Friedman, MD
(Am J Dermatopathol 2020;42:889)
(Continued from page e149)
ANSWER
Chronic myelogenous leukemia cutis.
DISCUSSION
Histopathologic review of the punch biopsy specimen
revealed a deep polymorphous infiltrate filling the subcutaneous
septae and intercalating between adipocytes. The infiltrate
consisted of extravasated erythrocytes, neutrophils, eosinophils,
mononuclear, and occasional multinucleated cells. Many of the
granulocytes had an immature appearance with hyposegmented
nuclei and a high nuclear-to-cytoplasmic ratio. A concurrent
bone marrow biopsy and peripheral blood evaluation revealed
findings diagnostic of chronic myeloid leukemia (CML) with
5%–8% blasts. Differential diagnosis for the skin histopathology
included extramedullary hematopoiesis verus cutaneous involve-
ment of CML (leukemia cutis). To differentiate among these
possibilities, fluorescence in situ hybridization (FISH) was per-
formed on the skin biopsy specimen for t(9;22) BCR-ABL1.
This gene fusion was identified in 75% of the nuclei, confirming
the diagnosis of chronic myelogenous leukemia cutis (Fig. 1).
CML presenting with cutaneous infiltrates is an excep-
tionally rare phenomenon occurring in only up to 2% of
patients1,2 and is more typically reported in the setting of blast
crisis. In this case, the infiltrate was rather polymorphous, and
blasts were not increased, thus not meeting diagnostic criteria
for acute myeloid leukemia (ie, myeloid sarcoma). In view of
the concurrent diagnosis of CML in the bone marrow and
peripheral blood and the FISH study on the skin being pos-
itive for t(9;22), the cutaneous infiltrate was best classified as
an extramedullary manifestation of CML. Establishing the
diagnosis relied on detection of the BCR-ABL1 fusion on
the skin biopsy through FISH, which to the best of our knowl-
edge, has not been reported previously in this context. The
patient was promptly started on hydroxyurea 40 mg/kd/d and
transitioned to imatinib, an inhibitor of the BCR-ABL tyro-
sine kinase. Owing to a subpar response to therapy with im-
atinib, a switch was then made to the newer tyrosine kinase
inhibitor dasatinib.
Leukemia cutis in general may precede frank development
of leukemia by months to years.1 It is most often seen with acute
myeloid leukemia, specifically in acute myelomonocytic leuke-
mia and acute monocytic leukemia.1–3 Morphology is variable
and can range from gingival hypertrophy to cutaneous papules,
plaques or nodules involving the head, neck, trunk, and extrem-
ities to a generalized morbilliform eruption.1 In this case, the
skin lesions presented as subcutaneous nodules closely resem-
bled erythema nodosum. The mechanism of leukemia cutis is
largely unknown, although chemokine receptors such as CCR4
and adhesion molecules such as cutaneous lymphocyte associ-
ated antigen may play a role in skin tropism of leukemic cells.4
Traditionally, leukemia cutis is associated with a poor prognosis
and is believed to reflect more advanced systemic involvement
of the disease.5 Treatment of the leukemia cutis involves treating
the underlying leukemia, and it should be noted that the time to
onset of resolution of the leukemia cutis is not predictive of the
overall prognosis.3
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FIGURE 1. Molecular fluorescence in situ hybridization revealing
presence of t(9;22) BCR-ABL1 gene fusion.
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